Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Kinase inhibitors that enter clinical use as treatments for cancer may have off-target effects, making them efficacious in the treatment of autoimmune diseases. Case reports are presented on the potential of erlotinib and gefitinib for treating psoriasis, inflammatory bowel disease, rheumatoid arthritis, and other nonautoimmune inflammatory disorders.